Clinical data including deep remission
Data vs STELARA® (ustekinumab)
3-year GALAXI open-label LTE data
time
First SC induction dose in as fast as 1 day‡
The patient support and resources provided by TREMFYA withMe are not intended to give medical advice, replace a treatment plan from the patient's healthcare provider, offer services that would normally be performed by the provider's office, or serve as a reason to prescribe TREMFYA.
†"Only" based on approved selective IL-23 inhibitors across both moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis as of September 2026. Compared to Skyrizi® (risankizumab-rzaa) and Omvoh® (mirikizumab-mrkz) induction and maintenance dosing. Skyrizi® and Omvoh® are not approved as SC induction therapy across both Crohn’s disease and ulcerative colitis.
‡See program requirements for the TREMFYA withMe Trial Offer at TREMFYAwithMeTrial.com.
APP=advanced practice provider; LTE=long-term extension.
STELARA is indicated for the treatment of adults with moderately to severely active Crohn’s disease. For more information on STELARA, please read the full Prescribing Information and Important Safety Information.
Not actual size.
When patients were asked to select which device they prefer:
~9out of10
preferred an SC pen
over an on-body injector (OBI) for treatment management7§||
§In a third-party 2025 unbranded market research survey, 506 patients with Crohn's disease or ulcerative colitis were asked to choose which administration method they would prefer for the treatment of disease between an SC injection pen and an SC OBI injection device. It did not evaluate efficacy or safety. While these factors are important, there are additional considerations for selecting treatment.7
§In a third-party 2025 unbranded market research survey, 506 patients with Crohn's disease or ulcerative colitis were asked to choose which administration method they would prefer for the treatment of disease between an SC injection pen and an SC OBI device. It did not evaluate efficacy or safety. While these factors are important, there are additional considerations for selecting treatment.7
||TREMFYA does not offer an SC OBI device.
Recommended Dosing for Crohn's Disease:
•Induction Dose: 400 mg administered by SC injection (given as two consecutive injections of 200 mg each) at Weeks 0, 4, and 8 or 200 mg administered by intravenous infusion over at least one hour at Weeks 0, 4, and 8
•Maintenance Dose: 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response
Pretreatment Evaluations: Evaluate for tuberculosis (TB) infection, evaluate liver enzymes and bilirubin levels, and complete all age-appropriate vaccinations according to current immunization guidelines.1
Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA; liver enzymes and bilirubin levels for at least 16 weeks of treatment, and periodically thereafter according to routine patient management.1
TREMFYA is intended for use under the guidance and supervision of a healthcare professional. After proper training in subcutaneous injection technique, adults may self-inject.1
TREMFYA is available as a pen, syringe, and the One-Press patient-controlled injector. Please see instructions for use.
